Oriola-KD Oyj B (ORIOLA)

Helsinki
Currency in EUR
1.080
+0.008(+0.75%)
Closed·
ORIOLA Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
High dividend Yield
Fair Value
Day's Range
1.0701.090
52 wk Range
0.8731.156
Key Statistics
Edit
Prev. Close
1.08
Open
1.074
Day's Range
1.07-1.09
52 wk Range
0.873-1.156
Volume
96.8K
Average Volume (3m)
142.05K
1-Year Change
13.45%
Book Value / Share
0.73
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
ORIOLA Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
1.183
Upside
+9.57%
Members' Sentiments
Bearish
Bullish
ProTips
High shareholder yield
Show more

Oriola-KD Oyj B Company Profile

Oriola Oyj engages in the wholesale of pharmaceuticals and health products in Sweden, Finland, and internationally. The company also distributes vitamins, food and food supplements, sports nutrients, wound care, beauty, and makeup related products; vaccines; and over-the-counter products. In addition, it provides pharmaceutical logistics; special licensed medicine importing, dose dispensing, and research pharmacy services; and commercial data, clinical trial, regulatory affairs and quality, medical and scientific affairs, market access and tenders, real world evidence, sales support, medical translation, pharmacovigilance and medical information, and patient support services. Further, the company provides advisory services. It serves pharmaceutical companies, pharmacies, veterinarians, hospitals, healthcare providers, special stores, retailers, and e-commerce companies. Oriola Oyj was founded in 1907 and is headquartered in Espoo, Finland.

Employees
845
Market
Finland

Oriola-KD Oyj B Earnings Call Summary for Q4/2024

  • Oriola-KD Oyj B reported 3% organic net sales growth and 30% increase in adjusted EBIT to €21.6 million in Q4 2024
  • Stock declined 3.13% pre-market despite positive results, reflecting concerns over market share and consumer confidence
  • Company expects adjusted EBITDA to increase in 2025, aims for market-standard performance for Kronan's Apotheque by 2027
  • Proposed dividend of $0.07 per share; maintains 6.85% dividend yield according to InvestingPro data
  • Faces challenges including weak consumer confidence, market share decline in Sweden, and cost inflation pressures
Last Updated: 2025/03/04, 10:54
Read Full Transcript

Compare ORIOLA to Peers and Sector

Metrics to compare
ORIOLA
Peers
Sector
Relationship
P/E Ratio
−8.5x20.3x−0.5x
PEG Ratio
−3.940.620.00
Price/Book
1.5x2.3x2.6x
Price / LTM Sales
0.1x1.1x2.9x
Upside (Analyst Target)
6.3%28.1%53.0%
Fair Value Upside
Unlock24.9%8.9%Unlock

Analyst Ratings

2 Buy
2 Hold
0 Sell
Ratings:
4 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 1.183
(+9.57% Upside)

Dividends

Payout Ratio
Payout ratio (TTM)
Earnings retained
EPS -0.13%
Dividend Yield
6.53%
Industry Median 4.22%
Annualised payout
0.07
Paid annually
5-Years Growth
-4.90%
Growth Streak

Earnings

Latest Release
Apr 29, 2025
EPS / Forecast
-0.011 / 0.0091
Revenue / Forecast
447.05M / 406.00M
EPS Revisions
Last 90 days

FAQ

What Is the Oriola-KD Oyj B (ORIOLA) Stock Price Today?

The Oriola-KD Oyj B stock price today is 1.08

What Stock Exchange Does Oriola-KD Oyj B Trade On?

Oriola-KD Oyj B is listed and trades on the Helsinki Stock Exchange stock exchange.

What Is the Stock Symbol for Oriola-KD Oyj B?

The stock symbol for Oriola-KD Oyj B is "ORIOLA."

Does Oriola-KD Oyj B Pay Dividends? What’s The Current Dividend Yield?

The Oriola-KD Oyj B dividend yield is 6.48%.

What Is the Oriola-KD Oyj B Market Cap?

As of today, Oriola-KD Oyj B market cap is 195.92M.

What Is Oriola-KD Oyj B's Earnings Per Share (TTM)?

The Oriola-KD Oyj B EPS (TTM) is -0.13.

When Is the Next Oriola-KD Oyj B Earnings Date?

Oriola-KD Oyj B will release its next earnings report on 17 Jul 2025.

From a Technical Analysis Perspective, Is ORIOLA a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Buy.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.